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Uncovering the signaling landscape controlling
breast cancer cell migration identifies novel
metastasis driver genes
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Ttriple-negative breast cancer (TNBC) is an aggressive and highly metastatic breast cancer
subtype. Enhanced TNBC cell motility is a prerequisite of TNBC cell dissemination. Here, we
apply an imaging-based RNAi phenotypic cell migration screen using two highly motile TNBC
cell lines (Hs578T and MDA-MB-231) to provide a repository of signaling determinants that
functionally drive TNBC cell motility. We have screened ~4,200 target genes individually and
discovered 133 and 113 migratory modulators of Hs578T and MDA-MB-231, respectively,
which are linked to signaling networks predictive for breast cancer progression. The splicing
factors PRPF4B and BUD31 and the transcription factor BPTF are essential for cancer cell
migration, amplified in human primary breast tumors and associated with metastasis-free
survival. Depletion of PRPF4B, BUD31 and BPTF causes primarily down regulation of genes
involved in focal adhesion and ECM-interaction pathways. PRPF4B is essential for TNBC
metastasis formation in vivo, making PRPF4B a candidate for further drug development.
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Breast cancer is the most prevalent cancer in women. The triple-negative breast cancer (TNBC) subtype which lacks expressionof the estrogen, progesterone and HER2 accounts for ~15% of
breast cancer. TNBC is the most aggressive BC subtype with an
overall 5 year relapse of 40% due to primary and secondary meta-
static spread1,2. Transcriptomics has classified four different mole-
cular subtypes of TNBC genes3 while proteomics studies revealed
markers of disease progression4. More recently, genome-wide
sequencing of large numbers of human breast cancers have defined
the somatically acquired genetic variation in breast cancer including
TNBC5–7 as well as the genetic evolutionary programs associated
with local and distant metastatic spread8,9. Although the roles of
individual genes in breast cancer metastasis10–13 have been described,
and few pooled shRNA screens have identified regulators of cancer
metastasis14,15 a systematic analysis of the functional consequences of
genetic aberrations in TNBC for progression towards metastatic
disease is still lacking.
The most critical cell biological hallmark of TNBCmetastasis is the
increased plasticity of TNBC cells16,17. Many TNBC cell lines have
adapted towards a mesenchymal phenotype and demonstrate a high
migratory behavior in association with an increased metastatic
spread11,18,19. Cell migration is involved in various steps of the
metastatic cascade, including local invasion, intravasation, extra-
vasation, and colonization of secondary sites20. Understanding the
fundamentals of TNBC cell migration is critical for our compre-
hension of the development of metastatic disease. The control of cell
migration is complex and involves components of the cell adhesion
machinery as well as modulators of the actin cytoskeleton that
coordinate cellular motility behavior21,22. The functionality of these
machineries is controlled by signaling pathways and associated
transcriptional programs that coordinate the expression of these cell
adhesion and cytoskeletal modulators as well as their post-
translational modification and activity23. While the signaling path-
ways that control TNBC proliferation have been uncovered using
genome-wide cell survival screens24,25 the role of individual cell
signaling components that define TNBC motility behavior is less
clear.
Here we systematically unraveled the global cell signaling land-
scape that functionally control TNBC motility behavior through a
phenotypic imaging-based RNAi-screen to identify genes involved in
the regulation of different migratory phenotypes. We discover genes
including several transcriptional modulators, e.g., PRPF4B, BPTF, and
BUD31, that define TNBC migratory programs and metastasis for-
mation, which are associated with poor clinical outcome of breast
cancer and share signaling networks underlying prognostic gene
signatures for primary breast cancer.
Results
A high-throughput RNAi screen for TNBC cell migration. We
selected two of the most highly motile TNBC cell lines Hs578T
and MDA-MB-231 for microscopy-based RNAi screening using
the PhagoKinetic Track (PKT) assay (Fig. 1a, Supplementary
Fig. 1, Supplementary movies 1 and 2; and described pre-
viously26). Briefly, cells were seeded on fibronectin containing a
thin layer of discrete latex beads that are phagocytosed during cell
migration, leaving behind individual migratory tracks. Track-
related image-analysis included quantification of net area, major/
minor axis, axial ratio, and roughness, defining the tumor cell
migration behavior. In contrast to live cell migration assays, this
assay can be applied in a high-throughput manner for genetic
screening of TNBC cell migration26,27. We focused our screening
effort on the complete set of cell signaling components, covering
all kinases, phosphatases, (de)ubiquitinases, transcription factors,
G-protein coupled receptors, epigenetic regulators, and cell
adhesion-related molecules (4198 individual target genes in total,
SMARTpool siRNAs (pool of four single siRNAs per target)).
Quantitative output data were normalized (robust Z-score) to
mock transfected control cells. High and low Z-scores of indivi-
dual parameters already showed the effect of siRNA knockdown
on cell motility, i.e., low net area or low axial ratio suggests
inhibition of cell migration whereas high axial ratio and high
major axis indicated enhanced motility (Fig. 1c, d). Even though
the quantification provided eight parameters, all the different
migratory phenotypes were not fully represented by single para-
meters. Therefore, migratory tracks were manually curated and
assigned to specific phenotypes by setting thresholds on Z-score
for the most dominant parameters of each phenotype after which
primary hits were determined based on these Z-scores (described
in the methods section). The migratory phenotypes were visua-
lized by principal component analysis (PCA)-based clustering
(Fig. 1e, f). For all phenotypes together, we defined 2807 hits in
total: 1501 primary hits for Hs578T and 1306 for MDA-MB-231.
Cytoskeletal genes, which are known to be important in cell
migration and might provide regulatory feedback loops, were not
enriched in these primary hit lists (Supplementary Fig. 2).
Importantly, there was no correlation between proliferation
(number of tracks) and any of the phenotypic parameters, sug-
gesting that hit selection was mainly based on effects on migra-
tion (Supplementary Fig. 3). However, we cannot exclude that
effects on cell proliferation could contribute to the inhibition of
cell migration for some candidates, in particular for those that
showed a decrease in track number. We identified 129 over-
lapping hits showing similar effects on cell migration upon
knockdown in both cell lines, suggesting these were bona-fide cell
line-independent drivers of tumor cell migration. Hence we
selected these overlapping hits for validation by single siRNA
sequences. Additionally, to obtain a larger coverage of genes
regulating cell migration that would uncover a more cell type
specific migratory behavior, we also selected the top 153 hits in
each cell line for validation. Only genes that have been defined as
druggable were validated, resulting in validation of 451 unique
targets (129 overlapping hits, 153 Hs578T unique hits and 153
MDA-MB-231 unique hits) (Supplementary Fig. 1 and Supple-
mentary Data 1).
To validate the primary hits, we repeated the PKT screen assays
with both SMARTpool and four single siRNA sequences (Fig. 2a and
Supplementary Fig. 1). In total, 217 (77%) hits were validated in the
Hs578T and 160 (57%) in the MDA-MB-231 (significant effects for
at least two singles and SMARTpool, for Hs578T see Fig. 2b; for
MDA-MB-231 see Supplementary Fig. 4; all validated genes are in
Supplementary Data 2; reproducibility is shown in Supplementary
Fig. 5 and Supplementary Fig. 6). The majority of validated hits was
found in the phenotypic classes of reduced cell migration (Fig. 2c); 65
validated candidate genes showed inhibition of cell migration in both
cell lines (Fig. 2d). This relatively low overlap of candidates cannot be
attributed to cell line specific mutations, copy number alterations or
differences in expression levels of the candidates (Supplementary
Fig. 7, information about mutation type in Supplementary Data 3) or
genes in pathways enriched for cell line specific candidates
(Supplementary Fig. 8). Annotation of protein classes for each set
of validated hits (Hs578T, MDA-MB-231, and overlap) showed that
most of the hits were transcription factors (Fig. 2e i) also after
correction for library size (Fig. 2e ii), suggesting that transcriptional
regulated gene networks are critical drivers of TNBC cell migration
behavior.
Transcriptional determinants are drivers of BC migration.
Next we evaluated the effect of all validated hits on cell migration
using a live microscopy cell migration assay with GFP-expressing
Hs578T and MDA-MB-231 cells (Supplementary Data 4 and 5).
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Fig. 1 A phenotypic, imaging-based, RNAi screen identifies regulators of tumor cell migration. a Live cell imaging of Hs578T and MDA-MB-231 phagokinetic
tracks. Scale bar is 100 µm. b Schematic representation of PKT screen. Transfection was performed in 96-well plates and controls were included in each plate.
After 65 h, transfected cells were washed, trypsinized, diluted and seeded in PKT assay plates. Plates were fixed after 7 h of cell migration and whole-well
montages were acquired using transmitted light microscopy. For each siRNA knockdown, a robust Z-score was calculated for each PKT parameter. All
screening experiments were performed in technical and biological duplicates. c The three most dominant quantitative PKT parameters are shown for Hs578T,
and d MDA-MB-231. Representative images of migratory tracks for genes with strong effect are shown below each graph and highlighted for enhancement
(red) and inhibition (green). e Principal component analysis of migratory phenotypes in Hs578T, and f MDA-MB-231. Migratory phenotypes were identified
manually and corresponding Z-scores were determined (see the methods section for more details). Only hits in each phenotypic class and mock control are
plotted, and representative images of each phenotype are shown. g Overlap of hits in each phenotypic class in both Hs578T and MDA-MB-231
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Fig. 2 Candidate migratory gene validation by deconvolution PKT screen. a Representative images of valid candidate genes using four individual single
siRNAs in three phenotypic classes are shown. Scale bar is 100 µm. b A total of 282 selected genes were tested in a deconvolution PKT screen with four
single siRNAs per gene. SMARTpool and single siRNA Z-scores of Net Area and Axial Ratio are shown for the overlap hits that were validated in Hs578T.
Average of biological and technical duplicates. c Distribution of validated candidate genes in the five phenotypic classes. d Overlap of validated hits
between Hs578T and MDA-MB-231. e Distribution of the validated genes involved in tumor cell migration in Hs578T, MDA-MB-231 over the different
libraries based on validated hits effective in both cell lines. Statistical significance was determined using a Fisher’s exact test. *p < 0.05
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Live cell imaging with Hs578T cells confirmed 133 of the 217 hits
to inhibit cell migration. Similarly, for the MDA-MB-231 cells,
113 candidate genes (out of 160 validated hits) were confirmed to
regulate cell migration. Upon knockdown, 31 PKT overlap can-
didates inhibited cell migration in this assay in both cell lines
(Fig. 3a, b and Supplementary Movies 3–14), including various
transcriptional and post-transcriptional regulators such as
RUNX1, MTF1, PAX7, ZNF141, SOX14, MXD1, ZNF446,
TARDBP, TBX5, BPTF, TCF12, TCERG1, ZDHHC13, BRF1, some
of which are directly involved with splicing (BUD31 and PRPF4B)
or histone modification (HDAC2 and HDAC10). For cell line
specific validated hits, we filtered candidate genes for which the
expression was associated with clinical breast cancer metastasis-
free survival (MFS) in a patient dataset (the Public-344 cohort,
GSE5237, and GSE2034, Supplementary Data 6). Many of the hits
associated with poor outcome inhibited cell migration in both
Hs578T and MDA-MB-231 (Fig. 3a, b, see Supplementary Data 4
and 5 for all candidate genes). Combined with the overlap can-
didates this resulted in 43 genes that were common denominators
of cell migration. Single cell migratory trajectories were plotted
for genes affecting cell migration in both cell lines (Fig. 3c).
Furthermore, we confirmed the general role of our candidates in
random cancer cell migration by validation of several main
candidates by inducible CRISPR-Cas9 knockout in a live cell
migration assay (Supplementary Fig. 9), siRNA knockdown fol-
lowed by live cell migration assays in two additional TNBC cell
lines (Supplementary Fig. 10) and siRNA knockdown followed by
a traditional scratch assay (Supplementary Fig. 11A–D), all 3 days
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Fig. 3 Candidate genes directly affect TNBC cell migratory behavior. a Quantification of single cell migration speed of Hs578T-GFP cells after knockdown of
validated hits. Hs578T-GFP cells were transfected with siRNAs and cell migration was assessed by live microscopy. Hits that showed significant and
consistent effects in both replicates were considered as candidate genes (right panel). Median ± 95% confidence interval is shown and cell populations
were compared by Kruskal–Wallis test with Dunn’s post correction test. b Same as in a, with MDA-MB-231-GFP cells. c Single cell trajectories of cell
migration upon knockdown of PRPF4B, MXD1, BUD31, or BPTF in (i) Hs578T and (ii) MDA-MB-231 cell lines
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after knockdown. All of our tested candidates were also affecting
FBS-directed cell migration in MDA-MB-231 3 days after
knockdown, but not per se in Hs578T (Supplementary
Fig. 11E–F). This suggests that effects on random cell migration
cannot always be directly extrapolated to directed cell migration,
especially for the Hs578T cell line. The latter could be caused by
the use of fibronectin-coated plates for live cell imaging compared
to a polystyrene membrane without extracellular matrix (ECM)
coating for directed cell migration or differences in the duration
of the migration assays (from 7 h for the PKT assay until 22 h for
the directed cell migration assays). However, altogether we
demonstrated that our selected candidates robustly inhibited
random cell migration in various cell lines and assays.
Drivers of TNBC migration associate with BC progression. To
better understand the regulatory networks driving BC cell
migration, we used the larger lists of our PKT validated candidate
genes (217 for Hs578T and 160 for MDA-MB-231) to inform on
protein-protein interaction (PPI) networks that are involved in
Hs578T and MDA-MB-231 cell migration. KEGG pathway ana-
lysis of the PKT validated candidates not only confirmed the
potent role of transcriptional misregulation in cancer, but also
immune-related and splicing pathways in cancer cell migration
(Supplementary Fig. 12A). Next, KEGG pathway analysis was
performed on the first-order networks of our candidate genes and
revealed that similar pathways were affecting cell migration in
both cell lines, despite that the networks were constructed from
different candidate genes (Fig. 4a, b, Supplementary Data 7). We
identified cancer-related pathways such as pathways in cancer
and focal adhesion but also immune-related pathways such as
osteoclast differentiation and chemokine signaling. To further
investigate the connection of our candidate genes to cell migra-
tion and invasion, we correlated our signaling networks of three
established gene signatures associated with metastatic behavior
and cell migration: the Human Invasion Signature (HIS)28, the
Lung Metastasis Signature (LMS)29,30, and a 440-gene breast
cancer cell migration signature. Next, these three independent
gene signatures were used to generate minimum interaction PPI
networks, which only contained connecting nodes and seed
proteins. Both Hs578T and MDA-MB-231 networks show a solid
overlap with the 440-gene signature-derived network, with 156
and 145 genes overlapping (Hs578T and MDA-MB-231, respec-
tively) (Supplementary Fig. 12B). This notion is further
strengthened by the overlap of the Hs578T and MDA-MB-231
PPI networks with the LMS and HIS signature-based networks:
58 (LMS) and 90 (HIS) genes in overlap with Hs578T network,
and 53 (LMS) and 77 (HIS) genes with the MDA-MB-231 net-
work. Furthermore, each gene-signature-derived network showed
enrichment for the same KEGG pathways as the PPI networks
based on our candidate genes (Supplementary Data 7). Given the
high degree of overlap between these three gene signature-based
networks and lists of candidate genes, we constructed a single
zero-order network based on the combination of candidate genes
affecting cell migration in Hs578T and MDA-MB-231 (65 genes,
Fig. 4c). This revealed a sub-network linking eight transcriptional
regulators of which most already have been related to cancer
progression, including HDAC2, BPTF, BRF1, TAF11, TCF12, and
FOS31,32, but also a prominent role for SMADs that are normally
driven by TGF-β33. However, TGF-β treatment showed limited
effects on TNBC cell migration (Supplementary Fig. 13), sug-
gesting that the effect of SMADs on TNBC cell migration is not
dependent on TGF-β. Next we systematically investigated the
effect of knockdown of the 217 PKT validated hits for morpho-
logical changes in the highly polarized Hs578T cell line by actin
cytoskeleton staining, confocal imaging, and quantitative single
cell analysis (Supplementary Data 8). Hierarchical clustering
grouped our PKT validated hits in nine different clusters
(Fig. 4d). Both clusters 2 and 9 contained not only control
knockdown samples but also many genes that affected Hs578T
cell migration, suggesting that a decrease in migration does not
necessarily coincide with an overall change in cell morphology.
Not surprisingly, inhibition of cell migration was associated with
a wide variety of cellular morphologies. For example, we observed
candidates decreasing as well as increasing cell area and cell
spikes (reflecting the number of cell protrusions). In vivo, loss of
cell adhesion and increased motility are both prerequisites for
metastasis formation. However, in vitro, our candidates could
inhibit cell migration via different mechanisms such as (1)
increased cell-cell adhesions, (2) decreased cell-matrix interac-
tions, and (3) decreased actin turnover that can result in different
cell phenotypes. Our combined data suggest that cell shape and
motility are affected independently and indicates different genetic
programs that define BC cell migration behavior.
Drivers of cell migration are associated with BC metastasis. To
further relate our candidate genes to breast cancer progression
and metastasis formation in patients, we compared our genes to
three prognostic signatures (Wang’s 76 genes, Yu’s 50 genes and
NKI-70) for breast cancer metastasis34–36. Despite the minimal
overlap of genes, these prognostic gene signatures have many
related pathways in common34 and minimum interaction PPI
networks showed a robust overlap with our Hs578T and MDA-
MB-231 cell migration networks based on PKT screen candidates
(217 for Hs578T and 160 for MDA-MB-231) (Fig. 5a and Sup-
plementary Data 9). These three gene expression signatures are
strongly predictive of a short time to metastasis, implying but not
yet statistically proven that our candidate genes are part of bio-
logically functional regulatory networks and pathways critical in
early onset of breast cancer metastasis.
Moreover, we investigated the percentage of mutations,
amplifications and deletions (together % altered) of the 43
candidate genes that affected migration in both cell lines (Fig. 3a,
b) in 29 cancer types using publicly available data from The
Cancer Genome Atlas (TCGA) (Fig. 5b). We identified clusters of
candidate genes highly altered in multiple cancer types, among
which breast cancer. This alteration rate was not related to tumor
type aggressiveness (Supplementary Fig. 14). For the main factors
including BPTF, BUD31, CACNG1, RUNX1, GRK1, PTPRS,
PRPF4B, and PBX1, most of these genetic alterations in breast
cancer are dominated by amplifications (Fig. 5c), suggesting that
enhanced expression levels of these candidates might be involved
in breast cancer initiation or progression. Candidate amplification
rates were not increased in the more aggressive primary tumors
that already metastasized at diagnosis (Supplementary Fig. 15),
which might be due to the rather small group of primary tumors
with developed metastases (22 tumors in total). 14 candidates
among which BUD31 and PRPF4B demonstrated a significant
higher amplification rate in TNBC compared to the ER-positive
subtype (Supplementary Fig. 16). Consequently, we also evaluated
the association of the gene expression of these 43 candidate genes
with MFS in the Public-344 cohort (Fig. 5d, Supplementary
Data 10). Interestingly, high expression levels of both splicing
factors PRPF4B and BUD31 are associated with earlier metastasis
formation in triple-negative and ER-positive tumors, respectively
(Fig. 5d), but not in the other subtypes (Supplementary Fig. 17).
Non-core splicing factor PRPF4B is a serine/threonine-protein
kinase regulating splicing by phosphorylation of other spliceoso-
mal components37. BUD31 is a core splicing factor essential for
spliceosome assembly, catalytic activity and associates with
multiple spliceosome sub-complexes and has shown to be a
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MYC target in MYC-driven cancer cells38. We also identified the
transcription factor BPTF, known for its role in chromatin
remodeling and mammary stem cell renewal and differentia-
tion39,40, that is highly amplified in many cancer types and
significantly positively correlated to MFS in breast cancer patients
irrespective of the subtype (Fig. 5d, Supplementary Fig. 17). We
further focused on splicing factors PRPF4B, BUD31, and
transcription factor BPTF, since these were newly identified
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Fig. 4 Regulatory networks drive tumor cell migration. a Enrichment of KEGG pathways in PPI networks generated from Hs578T candidate genes
and b MDA-MB-231 candidate genes. NetworkAnalyst was used to generate PPI networks. c Zero-order interaction network of combined Hs578T and
MDA-MB-231 candidate genes reveals a highly connected sub-network of clinically associated genes (in blue). Candidate genes inhibiting cell migration in
both cell lines are shown in red; central hubs are highlighted in green. The degree of connectivity (number of connections) is displayed on the right.
d Phenotype-based clustering of the PKT validated candidate genes based on morphological changes in the Hs578T cell line. Per parameter, log2 fold
change (FC) compared to mock control was calculated. Clustering was performed based on Euclidean distance and complete linkage
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modulators of cell migration associated with BC MFS and/or
highly amplified in BC.
PRPF4B, BUD31, and BPTF modulate cell-matrix adhesion.
Next, we performed knockdown of PRPF4B, BUD31, and BPTF in
MDA-MB-231 and Hs578T cells, followed by next-generation
sequencing (NGS)-based transcriptome analysis. For all three
candidate genes, knockdown efficiency was >90% in Hs578T cells
and >80% in MDA-MB-231 cells (Supplementary Fig. 18A, RT-
qPCR validation Supplementary Fig. 19). PRPF4B, BUD31, and
BPTF knockdown did not significantly affect proliferation in
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these cell lines (Supplementary Fig. 20). We identified differen-
tially expressed genes (DEGs; log2FC <−1 or > 1; adjusted
p-value < 0.05) for siPRPF4B, BUD31, and BPTF (Supplementary
Data 10). Notably, expression levels of other validated screen
candidates available in our RNA-sequencing dataset were not
specifically affected by knockdown of PRPF4B, BUD31, or BPTF,
indicating that these genes uniquely modulate transcriptional
programs that drive TNBC cell migration (Supplementary
Fig. 21). Knockdown of BUD31 had the broadest effect on gene
expression and caused downregulation of 1119 genes in Hs578T
and 929 in MDA-MB-231, with ~50% affected genes overlapping
between the two cell lines (Supplementary Fig. 18B–D). There
was limited overlap in the DEGs between PRPFB4, BUD31, and
BPTF (Supplementary Fig. 18E). Since PRPF4B and BUD31 are
both splicing factors, we investigated the effects of knockdown of
these candidates on alternative splicing patterns (Supplementary
Fig. 22, Supplementary Data 11–13). Depletion of the core spli-
ceosomal protein BUD31 mainly increased intron retention
(inclusion difference > 10% and P-adjusted < 0.01) (Supplemen-
tary Fig. 22A and C)38. As might be expected from a non-core
splicing factor, PRPF4B depletion only increased a small number
of introns retained (Supplementary Fig. 22B and 22C). All tested
intron retention events were validated with RT-PCR (Supple-
mentary Fig. 23), indicating that the computational pipeline we
used is reliable. Although the general relation between intron
retention and decreased gene expression was previously con-
firmed41–43, future studies have to validate the direct causal
relationships in response to PRPF4B and BUD31 knockdown. A
low number of genes was affected by 3’ or 5’ alternative splice site
usage or alternative exon inclusion upon splicing factor knock-
down (Supplementary Data 12), with a limited cell line overlap
(Supplementary Fig. 24). This is probably caused by the insuffi-
cient sequencing depth (20 million reads compared to 100 million
reads recommended) for alternative splicing analysis, prohibiting
a definite overall conclusion on differential splicing events. Since
siBUD31-induced intron retention was related to reduced gene
expression, we focused on the differentially downregulated genes
for further analysis. We also performed KEGG pathway over-
representation analysis using the significantly downregulated
genes for all hits in both cell lines separately using Con-
sensusPathDB44. Although the overlap in DEGs between different
cell lines and knockdown conditions was rather limited, the
ECM-receptor interaction was over-represented in all knock
down conditions (Fig. 6a, Supplementary Fig. 25A). Gene set
enrichment analysis (GSEA)45 confirmed this strong down-
regulation of the ECM-receptor interaction pathway (Fig. 6b,
Supplementary Fig. 25B). Moreover, knockdown of PRPF4B,
BUD31 and BPTF resulted in downregulation of the focal adhe-
sion pathway in both cell lines, except for BPTF in Hs578T. We
also observed candidate specific responses such as immune sig-
naling for PRPF4B (Fig. 6a), cell adhesion for BPTF and metabolic
and PI3K related pathways for BUD31 (Supplementary Fig. 25A).
Also, deregulated TNF signaling was validated for all three
knockdowns (Supplementary Fig. 26). Clustering of all genes
involved in ECM-receptor interaction (Fig. 6c, see Supplementary
Fig. 27 for all gene names) or focal adhesion (Supplementary
Fig. 28) demonstrated the involvement of many different pathway
components of which some were overlapping between PRPFB4,
BUD31, and BPTF (Figs 6c, d). A similar downregulation was
observed at the protein level for several key components in both
cell lines (Fig. 6e, Supplementary Fig. 29C). The effects on dif-
ferential expression of cell-matrix adhesion components such as
integrins and focal adhesion kinase was also reflected in the dif-
ferent organization of focal adhesions and the F-actin network for
both PRPFB4, BUD31, and BPTF (Fig. 6f and Supplementary
Fig. 29A–B). In summary, both splicing factors PRPF4B and
BUD31 as well as the transcription factor BPTF modulate the
expression of various focal adhesion-associated proteins and
ECM-interaction signaling components in association with dis-
tinct cytoskeletal reorganization and decreased BC cell migration.
PRPF4B is essential for BC metastasis formation in vivo.
Finally, we investigated whether we could translate our in vitro
findings to an in vivo mouse model for BC progression. Using our
previously established orthotopic xenograft model, we predicted a
decrease in BC metastasis formation upon splicing factor PRPF4B
depletion. We selected PRPF4B because its depletion strongly
inhibited both random and directed cell migration in both
Hs578T and MDA-MB-231 cells (see Fig. 3c and Supplementary
Fig. 11) and, moreover, a role for PRPF4B in promoting TNBC
metastasis formation has not previously been demonstrated. We
established stable PRPF4B knockdown in the metastatic MDA-
MB-417.5 cell line that expresses both GFP and luciferase12,27,29
and contains similar basal PRPF4B levels as its parental MDA-
MB-231 cell line (Supplementary Fig. 30A-B). shPRPF4B MDA-
MB-417.5 cells demonstrated ~40% PRPF4B knockdown at RNA
as well as protein level (Fig. 7a–c) and similar as siRNA knock-
down, decreased wound healing and intron retention of DGKZ
and MAF1 (Supplementary Fig. 30C–H). shPRPF4B cells showed
an equal primary tumor growth compared to the two shCtrl cell
lines (Fig. 7d), which ensured identical time window for tumor
cell dissemination from the primary tumor and outgrowth of
macro-metastasis (Supplementary Fig. 31A–B). Interestingly,
PRPF4B was higher expressed in the borders of the primary
tumor (Supplementary Fig. 32), supporting its potential role in
invasion and metastasis formation. Bioluminescence imaging
demonstrated that lung metastatic spread was less abundant in
the PRPF4B knockdown group compared to control group
(Supplementary Fig. 31C). Both bioluminescent imaging of the
lungs ex vivo and counting of macrometastases in the ink injected
right lung revealed a significant decrease in metastasis formation
in mice engrafted with shPRPF4B cells (Figs. 7f, g), which was
also confirmed by a decreased lung weight (Supplementary
Fig. 31D). Ex vivo bioluminescence imaging of the liver, spleen,
heart, kidney, uterus, and axillar lymph node also showed a
decreased metastatic burden by shPRPF4B cells (Fig. 7e) con-
firmed by a decreased liver and spleen weight (Supplementary
Fig. 31E and 31F). Altogether, this demonstrates that PRPF4B
Fig. 5 Modulators of TNBC cell migration are related to BC metastasis-free survival. a Prognostic gene signatures were used to generate minimum interaction PPI
networks and compared to our candidate TNBC cell migration gene networks. Candidate genes affecting cell migration feed into similar networks essential for BC
progression and metastasis formation. b Hierarchical clustering (Euclidean distance, complete linkage) of genetic modifications (mutations, deletions and
amplifications combined) of 43 candidate genes in 29 cancer types. Data was derived from The Cancer Genome Atlas. Annotation shows the expression of the
candidates in relation to BC metastasis-free survival in different BC subtypes. P-values were calculated using Cox proportional hazards regression analysis, with
gene expression values as continuous variable and metastasis-free survival as end point. Genes marked in red and blue are highlighted in c. Red genes were
selected for further analysis. c Contribution of different genetic modifications to the rate in several highly mutated or amplified candidates. d Kaplan–Meier curves of
for expression of PRPF4B, BUD31, and BPTF and relation to metastasis-free survival in ERpos or TNBC breast cancer. Gene expression data of lymph-node-negative
BC patient cohort without prior treatment using optimal split was used to obtain the curves
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knockdown impairs general metastasis formation without show-
ing organ-specificity.
Discussion
TNBC is the most aggressive form of breast cancer with 40% of
patients dying from metastatic disease. New insights into TNBC
migration is highly needed for the identification of potential new
drug targets to modulate TNBC dissemination and possibly revert
metastatic disease. In the present study, we applied a multi-
parametric, high-content, imaging-based RNAi-screen covering
~4200 cell signaling components to unravel regulatory networks
in TNBC cell migration and discovered 133 and 113 migratory
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modulators in the Hs578T and MDA-MB-231 cell lines, respec-
tively. Splicing factors PRPF4B and BUD31 and transcription
factor BPTF were critical for TNBC cell migration, associated
with metastasis-free survival and affect genes involved in focal
adhesion and ECM-interaction pathways. Moreover, PRPF4B
knockdown reduced TNBC metastasis formation in vivo, making
it an important target for future drug development.
Since our screening effort focused on a broad set of cell sig-
naling components in two TNBC cell lines (Hs578T and MDA-
MB-231), we were able to cover a high number of genes and
networks in different migration modes. Indeed, the PKT assay
allowed us to quantitatively assess different migration pheno-
types, as the track morphology reveals the effect on migration,
persistence and membrane activity. Enhanced cell migration
proved to be difficult to validate, probably due to the increased
migratory phenotype in Hs578T and MDA-MB-231 reaching a
physiological ceiling. Additional screening with TNBC cell lines
with lower migratory potential would provide a platform to dis-
cover the spectrum of genes that may act as suppressors of TNBC
cell migration and metastasis formation. The majority of our
candidate genes displayed inhibition of cell migration and are
most interesting for translation to cancer metastasis. Importantly,
candidate migratory regulators, including SRPK1 and TRPM7,
have previously been shown to impair cell migration and
metastasis formation13,27, supporting the robustness of our can-
didate drug target discovery strategy.
Our work provides a comprehensive resource detailing the role
of individual signaling genes in cell migration. Previously, a cell
migration screen in H1299 (non-small cell lung carcinoma)
identified 30 candidate migration modulating genes27. Surpris-
ingly, there was little overlap with our validated genes, with the
exception of SRPK1. Similarly, little overlap in hits was found
with a wound-healing screen in MCF10A cells46. These differ-
ences are likely due to the coverage and size of the screening
libraries with the current screen covering ~4200 genes compared
to ~1400 genes in the previously published data. Moreover,
TNBC cell migration might be driven by different genetic pro-
gram than non-small cell lung carcinoma and MCF10A cells.
Also, the MCF10A screen focused on collective cell migration in
epithelial cells, which is distinct from single cell mesenchymal
migration in our two TNBC cell lines. Since ECM is a major
component of the local tumor microenvironment, all our
migration assays were performed on fibronectin-coated plates.
This coating significantly increased the migratory behavior of our
cells (Supplementary Fig. 33), which could also result in different
candidates compared to the previous reported MCF10A screen.
Moreover, none of the previously identified host-regulators of
metastases in mouse47 were validated in our screen. This might be
due to the small overlap (only seven of 23 regulators were in the
library) or general differences between in vitro human cell line
models and in vivo mouse models. For example, our in vitro cell
line models lack the tumor microenvironment containing among
others immune cells or tumor-supporting fibroblasts that can
modulate the metastatic response. However, the discrepancies
between these studies might also suggest that candidates from our
screening approach are particular involved in the first steps in the
metastatic cascade such as escaping the primary tumor and
intravasation rather than later steps such as extravasation, colo-
nization, and metastatic outgrowth.
The importance of our candidate TNBC cell migration mod-
ulators was supported by comparative bioinformatics-based net-
work analysis, demonstrating high similarities between cell
migration PPI networks in Hs578T and MDA-MB-231 and
metastatic and BC prognostic signatures35,28,29,34. Moreover, we
identified candidates that are highly amplified and/or mutated in
many cancer types as well as candidates specifically related to
breast cancer metastasis formation. Interestingly, two of these
candidates, PRPF4B and BUD31, were splicing factors suggesting
modulation of the expression of gene networks through alter-
native splicing. This is in line with some recent studies in which
multiple splicing factors and events were related to cancer pro-
gression48–50. In total, 43 splicing factors were represented in our
primary screen of which 11 were selected for further validation in
MDA-MB-231 (Supplementary Fig. 34), again suggesting a pro-
minent role for splicing regulation in breast cancer cell migration.
Moreover, others have linked more splicing factors such as the
hnRNPs, SRSF1, SRPK1, and PTBP1 to breast cancer migration
and metastasis formation27,51–54, making it very interesting to
systematically evaluate the role of splicing in breast cancer cell
migration in future studies.
Our list of candidate genes that regulate TNBC cell migration
expectedly also contributes to cancer metastasis. We selected
PRPF4B to assess whether our in vitro screening efforts can be
translated to in vivo inhibition of metastasis formation. Depletion
of PRPF4B strongly inhibited migration of both Hs578T and
MDA-MB-231 cells in vitro and almost completely prevented
spontaneous metastasis formation from the orthotopic primary
tumor to distant organs, indicating that PRPF4B seems essential
in metastasis formation. PRPF4B is a pre-mRNA splicing factor
kinase involved in the phosphorylation of PRP6 and PRP31 and
splicing complex formation. Yet, in our hands depletion of
PRPF4B showed little effect on intron retention patterns, sug-
gesting more subtle splicing effects. However, PRPF4B knock-
down did affect the expression of various components of the focal
adhesion and ECM signaling pathways, which is likely an
important contributor to the reduced migratory and metastatic
behavior. PRPF4B could be a relevant drug target to combat
TNBC dissemination and future research should focus on the
development of a specific PRPF4B inhibitor; the X-ray structure
of the catalytic domain of PRPF4B suggest this is feasible55. For
other potential candidates such as BPTF, the correlation with
metastasis-free survival added evidence that these candidate genes
are likely involved in cancer metastasis. Since these associations
do not prove a causal relationship, it would be very interesting to
investigate these candidates in similar in vivo studies.
Our list of highly confident candidate migratory modulating
genes provides ample opportunities for additional hypotheses and
studies in the field of cell migration. Sixteen G-protein coupled
Fig. 6 PRPF4B, BUD31, and BPTF depletion modulates ECM-receptor signaling. a Over-representation analysis of genes with decreased expression levels
(log2FC change <−1) after PRPF4B knockdown in Hs578T and MDA-MB-231 cells using pathways annotated in the KEGG database. b Gene Set
Enrichment Analysis (GSEA) identifies the ECM-receptor interaction pathway as significantly enriched in downregulated genes after PRPF4B knockdown in
Hs578T and MDA-MB-231 cell lines. c Hierarchical clustering (Euclidean distance, complete linkage) of log2FC in expression levels of genes involved in the
KEGG ECM-receptor interaction pathway after knockdown of candidates demonstrates that many genes involved in this pathway are downregulated after
candidate knockdown. d LAMA5, ITGB1, and ITGA3 expression upon depletion of PRPF4B, BUD31 and BPTF (mean+ s.d of three biological replicates, one-
way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). e Effect of PRPF4B, BUD31 and BPTF depletion on levels of different ECM and focal adhesion components
in MDA-MB-231 cells analyzed with western blot. f Effect of indicated gene depletion on focal adhesion and actin cytoskeleton organization. Hs578T cells
were fixed and stained against the actin cytoskeleton, p-FAK (Y397). Scale bar is 50 µm
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Fig. 7 PRPF4B is essential for breast cancer metastasis formation in vivo. amRNA and b protein expression of PRPF4B in shPRPF4B MDA-MB-417.5 cell line
compared to shCtrl#1 and shCrtl#2 MDA-MB-417.5 cell lines. Mean+ s.d. of three biological replicates. Statistical significance was determined using one-
way ANOVA correcting for multiple testing. *p < 0.05, **p < 0.01. c Immunofluorescent staining for PRPF4B (green) and DNA (DAPI; blue) in shCtrl#1,
shCtrl#2 and shPRPF4B MDA-MB-417.5 cell lines. Scale bar= 50 μm. d Tumor growth of shPRPF4B, shCtrl#1, and shCtrl#2 MDA-MB-417.5 cells
engrafted in the mammary fat pad of Rag2–/– Il2rg–/– mice (n= 7–8 animals per group). e Dissemination of shPRPF4B, shCtrl#1 and shCtrl#2 MDA-MB-
417.5 cells in the lung, liver, spleen, kidney, heart, uterus, and axillar lymph node as determined by ex vivo bioluminescent analysis (total flux (p/s)) of
different target tissues (n= 7–8 animals per group). f Number of lung metastases for shPRPF4B, shCtrl#1, and shCtrl#2 injected mice as determined by
macroscopic evaluation of lungs injected with ink (n= 7–8 animals per group). g Images of ink injected lungs (left) and bioluminescent signal in the lungs
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post correction test (luminescence) or ANOVA (metastasis count). *p < 0.05, **p < 0.01
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receptors were defined, which is particularly relevant as the
pathway of GPCR-signaling is one of top over-represented
pathways in ER-negative tumors34. Depletion of several ubiqui-
tinases and proteasome components (DTX3L, UBE2E1, RNF31,
RNF115, USP2, USP42, PSMC3, and PSMD10) were also found to
inhibit tumor cell migration. Protein homeostasis and proteasome
function have recently been suggested as a target for proliferation
and growth in basal-like TNBC56. Transcription factors and
regulators make up the largest group of candidate metastasis
genes. Some of these factors are part of a large interactive network
including HDAC2, BPTF, BRF1, TAF11, TCF12, and FOS. The
downstream targets of these transcription factors are potentially
driving BC cell migration, and/or other biological processes that
are critical for metastasis formation. Indeed BPTF knockdown
affected focal adhesion and ECM components in a similar fashion
as PRPF4B and BUD31 knockdown did.
In conclusion, in the present study we used imaging-based
phenotypic screening to identify candidate metastatic genes for
TNBC that have translational relevance. Understanding the gene
networks that are controlled by the various candidate genes
provides further insights in the biological programs that define
BC cell migration behavior and lead to important drug targets to
combat cancer metastasis.
Methods
Transient siRNA-mediated gene knockdown. Human siRNA libraries were
purchased in siGENOME format from Dharmacon (Dharmacon, Lafayette, CO,
USA). Transient siRNA knockdown was achieved by reverse transfection of 50 nM
single or SMARTpool (containing four different siRNAs) siRNA in a 96-well plate
format using the transfection reagent INTERFERin (Polyplus, Illkirch, France)
according to the manufacturer’s guidelines. Medium was refreshed after 20 h and
transfected cells were used for various assays between 65 and 72 h after transfec-
tion. Mock and/or siKinasePool were used as negative control. For the validation
screen, four different single siRNAs and one SMARTpool siRNA mix (same four
single siRNAs) were tested independently. For all other experiments, SMARTpool
siRNAs were used.
Stable shRNA-mediated gene knockdown. MDA-MB-417.5 cells were trans-
duced with lentiviral shRNA constructs coding for a non-targeting control
sequences shCtrl #1 (SHC002), shCtrl #2 (SHC202V) or a sequence targeting the
coding region of PRPF4B (target sequence: GCTTCACATGTTGCGGATAAT
(TRCN0000426824)) (Mission/Sigma–Aldrich, Zwijndrecht, The Netherlands).
The cells were selected by puromycin (sc-108071, Santa Cruz Biotechnology,
Heidelberg, Germany). Knockdown efficiency was verified by RT-qPCR, western
blot, and immunofluorescent staining.
Phagokinetic track (PKT) assay. PKT assays were performed as described
before26,57. For each transfection, duplicate bead plates were generated (technical
replicates); transfection of each siRNA library was also performed in duplicate
(independent biological replicate). Procedures for transfection, medium refresh-
ment and PKT assay were optimized for laboratory automation by a liquid-
handling robot (BioMek FX, Beckman Coulter).
PKT imaging and analysis. Migratory tracks were visualized by acquiring whole-
well montages (6 × 6 images) on a BD Pathway 855 BioImager (BD Biosciences,
Franklin Lakes, NJ, USA) using transmitted light and a ×10 objective (0.40 NA). A
Twister II robotic microplate handler (Caliper Life Sciences, Hopkinton, MA, USA)
was used for automated imaging of multiple plates. Montages were analyzed using
WIS PhagoTracker26. Migratory tracks without cells or with more than one cell
were excluded during image analysis. Quantitative output of PhagoTracker was
further analyzed using KNIME. Wells with <10 accepted tracks were excluded.
Next, data were normalized to mock to obtain a robust Z-score for each treatment
and each parameter. After normalization, an average Z-score of the four replicates
was calculated. Knockdowns with <3 images were removed, as well as knockdowns
with <60 accepted tracks for Hs578T and <150 accepted tracks for MDA-MB-231.
Phenotypic classes were determined based on Z scores of the track parameters:
small (net area Z score <−4), small round (net area < 8000, axial ratio < 1.7, net
area Z score <−1, axial ratio Z-score <−3), big round (net area > 8000, axial ratio
< 1.7, net area Z-score > 1, axial ratio Z-score <−4), long rough (axial ratio > 2.4,
major axis > 200, roughness > 5, axial ratio Z-score > 1, major axis Z-score > 1), and
long smooth (axial ratio > 2.1, major axis > 180, roughness < 5).
All PKT screening data will be available in the Image Data Resource database
upon publication and are currently available upon request.
Live single cell migration assay and analysis. Hs578T-GFP and MDA-MB-231-
GFP cells were transfected with siRNAs as described above and after 65 h,
knockdown cell suspensions were seeded in fibronectin-coated black 96-well glass
plates (SensoPlate, Greiner Bio-One, Frickenhausen, Germany). As controls,
siRNA targeting the GTPase dynamin 2 (DNM2) was used for reduced cell
migration and mock was used as transfection control. For the TGF-β and EGF
stimulation experiments, cells were seeded in fibronectin-coated black 96-well glass
plates (SensoPlate, Greiner Bio-One, Frickenhausen, Germany). Cells were starved
in serum-deprived RPMI for 2 h after which cells were stimulated with 10 ng/ml
TGF-β (Immunotools) or 100 ng/ml EGF (Peprotech). Imaging was directly started
after treatment. Live microscopy was performed on a Nikon Eclipse Ti microscope
using a ×20 objective (0.75 NA, 1.00 WD), 2 × 2 binning and 2 × 2 montageTwo
positions per well were selected and GFP images were acquired every 12 min for a
total imaging period of 12 h using NIS software (Nikon, Amsterdam, The Neth-
erlands). Image analysis was performed using CellProfiler (Broad Institute)58. For
live cell migration, images were segmented using an in-house developed watershed
masked clustering algorithm59, after which cells were tracked based on overlap
between frames. Tracking data was organized and analyzed using in-house
developed R-scripts to obtain single cell migration data. Only data originating from
cells that were tracked for a minimum of 2 h were used. Two negative control wells
with low and high cell densities, comparable to the knockdown populations, were
selected for statistical comparison, and knockdowns were required to be statistically
significant compared to both controls.
Imaging-based phenotypic screen. Hs578T cells were fixed and permeabilized in
1% formaldehyde and 0.1% Triton X-100 in PBS and blocked in 0.5% bovine serum
albumin (BSA, A6003, Sigma–Aldrich) in PBS. Cells were stained with Rhodamine
Phalloidin (R415, Molecular Probes) and imaged using an Nikon Eclipse TE2000-E
inverted confocal microscope (Nikon Instruments, Amsterdam, The Netherlands)
using a ×20 Plan Apo objective, 408, and 561 nm lasers. ×2 digital zoom, 2 ×
2 stitching images were captured at four positions per well. Nuclei and actin cell
body were detected by CellProfiler (Broad Institute) and parameters were measured
using the measure object size and shape module in CellProfiler. Images with more
than 150 cells were filtered out. Using KNIME, nuclei without a clear cell body
were rejected and single cell data were normalized to the median of 2 mock control
wells per plate. For the heatmap, all features were mock normalized and clustering
was performed on complete linkage and Euclidean distance.
Next-generation sequencing. RNA was collected 72 h after knockdown using the
RNeasy plus mini kit (Qiagen) according to the manufacturer’s guidelines. DNA
libraries were prepared with the TruSeq Stranded mRNA Library Prep Kit and
sequenced according to the Illumina TruSeq v3 protocol on an Illumina
HiSeq2500 sequencer. 20 × 106 100 base pair paired-end reads were generated and
alignment was performed using the HiSat2 aligner (version 2.2.0.4) against the
human GRCh38 reference genome. Gene expression was quantified using the
HTseq-count software (version 0.6.1) based on the ENSEMBL gene annotation for
GRCH38 (release 84). Count data were normalized and log2 fold changes and
adjusted P-values were calculated using the DESeq2 package60. Calculated log2 fold
changes were used to perform ranked GSEA45. DEGs were selected by effect size
(log2 fold change bigger than 1 or smaller than −1) and adjusted p-value (smaller
than 0.05) and used for over-representation analysis for KEGG pathways using
ConsensusPathDB44.
For the intron retention analysis, RNA-seq reads were mapped to the current
human genome (GRCh38) using Hisat 261. Differential intron retention analysis
was carried out in R using DexSeq package62,63. In DexSeq the difference of intron
inclusion were determined based the counts from the intron and the counts from
the two adjacent exons. The sizes of the exons were limited to 100nt immediately
adjacent to the intron to reduce artifacts deriving from alternative promoters,
alternative splice sites and alternative poly-adenylation sites. Deferentially retained
introns were selected by effect size (relative change in inclusion more than 0.1) and
statistical significance of the change (adjusted p-value less than 0.01). Alternative
exon inclusion was analyzed using the rMATS package version 3.0.864.
Differentially spliced exons were selected by effect size (relative change in inclusion
more than 0.1) and statistical significance of the change (FDR < 0.05).
RNA sequencing data are available in Sequence Read Archive with accession
number SRP127785.
Network analysis. Protein annotation of the primary hits was retrieved from
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, USA).
Protein-protein interaction (PPI) networks were generated separately for all sig-
natures using NetworkAnalyst (www.networkanalyst.ca)65. Candidate genes were
used as seed proteins to construct first-order, minimum interaction and zero-order
networks based on the InnateDB Interactome. KEGG pathway analysis was per-
formed on the first-order PPI networks. The connection between multiple PPI
networks was visualized by a Chord diagram using NetworkAnalyst.
Cell culture. Hs578T (ATCC-HBT-126) and MDA-MB-231 (ATCC-HBT-26)
were purchased from ATCC. MDA-MB-417.5 (MDA-LM2) was kindly provided
by Dr. Joan Massagué. All cell lines were grown in RPMI-1640 medium (Gibco,
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ThermoFisher Scientific, Breda, The Netherlands) supplemented with 10% FBS
(GE Healthcare, Landsmeer, The Netherlands), 25 IU/ml penicillin, and 25 µg/ml
streptomycin (ThermoFisher Scientific) at 37 °C in a humidified 5% CO2 incubator.
When not stated otherwise, experiments were performed in this full RPMI med-
ium. Stable GFP-expressing Hs578T and MDA-MB-231 cells were generated by
lentiviral transduction of pRRL-CMV-GFP and selection of GFP positive clones by
FACS. For live cell imaging, phenol red-free culture medium was used. All cell lines
used in this study are not listed in the database of commonly misidentified cell lines
maintained by ICLAC and were tested for mycoplasma contamination. The
authenticity of all the cell lines was checked by short tandem repeat (STR) profiling
using the PowerPlex® 16 System (Promega, Madison, WI, USA) including fifteen
STRs and one gender discriminating locus using 10 ng of genomic DNA isolated
with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) for the multiplex PCR.
The authenticity of the cell lines was assessed based on the source STR profiles of
the American Type Culture Collection (ATCC) and the Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ).
Antibodies and reagents. Rabbit anti-PRPF4B (8577, Cell Signaling Technology),
mouse anti-Tubulin (T-9026, Sigma–Aldrich), mouse anti-Paxillin (610052, BD
Biosciences), mouse anti-ITGB1 (610467, BD Biosciences), mouse anti-FAK
(610087, BD Biosciences), mouse anti-N-cadherin (610920, BD Biosciences),
mouse anti-E-cadherin (610181, BD Biosciences), rabbit anti-p-FAKY397
(446–24ZG, Thermo Fisher), and mouse anti-Vimentin (ab8069, Abcam) were all
commercially purchased. All antibodies were used in a 1:1,000 dilution. Rabbit
anti-ITGA3 and rabbit anti-Laminin5 were kindly provided by A. Sonnenberg
(NKI, Amsterdam, The Netherlands). Anti-mouse and anti-rabbit horseradish
peroxidase (HRP) conjugated secondary antibodies were purchased from Jackson
ImmunoResearch.
Cell migration scratch assay. Hs578T and MDA-MB-231 cells were transfected
with siRNAs as described above and after 65 h, knockdown cell were counted and
seeded (25,000 cells/well for Hs578T, 35,000 cells/well for MDA-MB-231, 35,000
cells/well for MDA LM2) in a fibronectin-coated black 96-well screenstar plate
(Greiner Bio-One, Frickenhausen, Germany). Six hour after seeding cells were
stained with Hoechst 33342 (1:10,000) for 1 h, scratches were made using a pipet
tip and the medium was refreshed. Live microscopy was performed on a Nikon
Eclipse Ti microscope using a ×4 objective. Images were acquired every hour for a
total imaging period of 22 h using NIS software (Nikon, Amsterdam, The
Netherlands).
Boyden chamber assay. Hs578T and MDA-MB-231 cells were transfected with
siRNAs as described above. 65 h after knockdown, cells were starved in serum-
deprived medium for 6 h. After starvation, 50,000 cells were plated in 0.3% FBS in
medium in ThinCert inserts (8 µm pore size, Greiner) which were placed in a 24-
wells plate filled with 600 µl medium containing 10% FBS or 0.3% FBS as a negative
control. After 22 h, the culture medium in the wells was replaced by 450 µl serum-
free medium containing 8 µM Calcein-AM (Sanbio/Caymen) and incubated for 45
min at 37 °C. Inserts were transferred to a freshly prepared 24-well culture plate
containing 500 µl pre-warmed trypsin-EDTA per well and incubated for 10 min at
37 °C. 200 µl of the trypsin-EDTA solution was transferred into a black flat bottom
96-well plate (µclear plate, Greiner) and fluorescence was measured with a
FLUOstar OPTIMA plate reader (BMG labtech, Offenburg, Germany) using an
excitation wavelength of 485 nm and emission wavelength of 520 nm.
Inducible CRISPR-Cas9 knockout. Inducible Cas9 cell lines were obtained by
transduction of MDA-MB-231 cell lines with lentiviral the Edit-R inducible len-
tiviral Cas9 plasmid (Dharmacon). Cells were selected using 2 µg/ml blasticidin and
grown single cell after which a clone was selected that was fully Cas9 inducible;
from no called MDA-MB-231 ind-Cas9. sgRNAs were obtained from the human
Sanger Arrayed Whole Genome Lentiviral CRISPR Library (Sigma–Aldrich)
(sgPRPF4B #1: ATGCCAGCCCCATCAATAGATGG, sgPRPF4B #2: GGAGCA-
GATCACGCTTGCGAAGG, sgBUD31 #1: ACAAAAACCTGATTGCAAAATGG,
sgBUD31 #2: ATGAGAACTTGTGCTGCCTGCGG, sgBPTF #1: CCGGATGA-
CATCAATTGAAAGAG, sgBPTF #2: AAACGATGCAGCAAGCGACATGG).
Inducible knockout cell lines were obtained by lentiviral transduction of the
sgRNAs into the MDA-MB-231 ind-Cas9 cell line after which the cells were
selected using 1 µg/ml puromycin. Cells were treated for 72 h with 1 µg/ml freshly
prepared doxycycline and western Blot and live cell migration assays were per-
formed as described above.
Immunofluorescence. Cells were fixed and permeabilized 72 h after knockdown
by incubation with 1% formaldehyde and 0.1% Triton X100 in PBS and blocked
with 0.5% w/v BSA in PBS. Cells were incubated with the primary antibody in 0.5%
w/v BSA in PBS overnight at 4 °C and incubated with the corresponding secondary
antibodies and 1:10,000 Hoechst 33258 for 1 h at room temperature. Cells were
imaged with a Nikon Eclipse Ti microscope and 60x oil objective.
Western blotting. Cell lysis and western blotting was performed as described
before (Zhang, 2011). Blots were visualized using the Amersham Imager 600 (GE
Healthcare). At least two biological replicates were performed per experiment.
Tubulin was used as a loading control. Uncropped gel images can be found in the
Source Data file.
PCR. Forty-eight hour after plating stable knockdown cell lines, total RNA was
extracted using RNeasy plus mini kit (Qiagen) followed by cDNA synthesis using
the RevertAid H minus first strand cDNA synthesis kit (Thermo Fisher Scientific)
both according to the manufacturer’s protocol. RT-qPCR was performed with the
SYBR Green PCR master mix (Thermo Fisher Scientific) on a 7500 Fast Real-Time
PCR machine (Applied Biosystems/Thermo Fisher Scientific). Conventional PCRs
were performed using MyTaq Red Mix (Bioline) according to the manufacturer’s
protocol. The following primers were used: PRPF4B forward: 5’-CCGAGGAGT
CAGGAAGTTCA-3’, PRPF4B reverse: 5’-TCTTTTCAGAATTAGCATCTTC
CAT-3’; GAPDH forward: 5’-CTGGTAAAGTGGATATTGTTGCCAT-3’,
GAPDH reverse: 5’-TGGAATCATATTGGAACATGTAAACC-3’; β-actin for-
ward: 5’-TCAAGATCATTGCTCCTCCTGAG-3’, β-actin reverse: 5’-
ACATCTGCTGGAAGGTGGACA-3’, CSF1 forward: 5’-CCCTCCCACGA-
CATGGCT-3’, CSF1 reverse: 5’-CCACTCCCAATCATGTGGCT-3’, CSF2 for-
ward: 5’-GCCCTGGGAGCATGTGAATG-3’, CSF2 reverse: 5’-
CTGTTTCATTCATCTCAGCAGCA-3’, IL6 forward: 5’-TCAATATTA
GAGTCTCAACCCCCA-3’, IL6 reverse: 5’-GAAGGCGCTTGTGGAGAAGG-3’,
MMP3 forward: 5’-CACTCACAGACCTGACTCGG-3’, MMP3 reverse: 5’-AGT
CAGGGGGAGGTCCATAG-3’, PIK3CD forward: 5’-
GTCCCCTGGGCAACTGTC-3’, PIK3CD reverse: 5’-GCCTGACTCCT
TATCGGGTG-3’, BUD31 forward: 5’-CATTCAGACACGGGACACCA-3’,
BUD31 reverse: 5’-ATGATGCGGCCCACTTCC-3’, BPTF forward: 5’-
GGCATCTTGCAAAGTGAGGC-3’, BPTF reverse: 5’-TATGGGCCTGTAAG
GAACGG-3’, DGKZ intron 7 forward: 5’-TGCTCGTGGTGCAAGCA-3’, DKGZ
intron 7 reverse: 5’-AGCATGAAGCAGGACACCTT-3’, POMGNT1 intron 20
forward: 5’-TGCCTCCATATCTGGGACCT-3’, POMGNT1 intron 2 reverse: 5’-
GTGACTGAGGGTGGCTTCTT-3’, MAF1 intron 4 forward: 5’-
ATCTGCCTGGCTGAATGTGAC-3’, MAF1 intron 4 reverse: 5’-GGATCT
GAGTCCAAGTCTGGGT-3’, CDCA5 intron 1 forward: 5’-AGTTATGTCTGG
GAGGCGAA-3’, CDCA5 intron 1 reverse: 5’-TCAGAGCCTGATTTCCGCT-3’,
CDCA5 intron 2 forward: 5’-AGCGGAAATCAGGCTCTGA-3’, CDCA5 intron 2
reverse: 5’-AGACGATGGGCTTTCTGACT-3’, SRRT intron 18 forward: 5’-
AGGCCAGGGAGGTTATCCT-3’, SRRT intron 18 reverse: 5’-
TTGGGTCTCCACGAACCAT-3’, ELAC2 intron 19 forward: 5’-AGATTGAT
CAGTTCGCTGTTGC-5’, and ELAC2 intron 19 reverse.
Relative gene expression was calculated after correction for GAPDH and β-actin
expression using the 2ΔΔCt method.
Orthotopic mouse model for metastasis assessment. 1 × 106 MDA-MB-
417.5 shCtrl #1, shCtrl #2, or shPRPF4B cells diluted in 100 μL matrigel (9.2 mg/
ml, 354230, batch 4321005, Corning, Amsterdam, The Netherlands) were injected
in the fourth mammary fat pad of 7–9-week-old female Rag2–/– Il2rg–/– mice (n=
8 per group: coefficient of variation= 0.2, effect size= 30%, power π= 0.90 bij α=
0.05). Primary breast tumors were surgically removed when they reached the size of
7 × 7 mm. Next, bioluminescent imaging was used to follow metastasis formation
over time. Mice were sacrificed 50 or 51 days after surgery and metastasis for-
mation of all organs was assessed by bioluminescent imaging followed by weighing
the lungs, liver, and spleen. The right lung was injected with ink in order to count
the number of lung macrometastases. Animals that passed away due to unknown
reasons before the end of the study were removed from the analysis. Animals were
randomly distributed over the different groups. The experiment was performed
without blinding.
Breast cancer patient gene expression profiles. Gene expression data of a
cohort of 344 lymph node-negative BC patients (221 estrogen receptor-positive
(ER-positive) and 123 estrogen receptor-negative (ER-negative)), who had not
received any adjuvant systemic treatment, were used and is available from the Gene
Expression Omnibus (accession no. GSE5327 and GSE2034). Clinical character-
istics, treatment details and analysis were previously described34,35,66–68. Stata
(StataCorp) was used to perform Cox proportional hazards regression analysis,
with gene expression values as continuous variable and MFS as end point.
Statistical analysis. Sample sizes were based on previously published similar
experiments. When not indicated, all experiments were performed in biological
triplicates. Normality of migration measurements and in vivo data were tested
using Kolmogorov–Smirnov’s test, d’Agostino and Pearson’s test and
Shapiro–Wilk’s test using GraphPad Prism 6.0 (GraphPad Software, San Diego,
CA). A data set was considered normal if found as normal by all three tests. Data
sets following a normal distribution were compared with Student’s t-test (two-
tailed, equal variances) or one-way ANOVA (for comparison of more than two
groups) using GraphPad Prism 6.0. Data sets that did not follow a normal dis-
tribution were compared using Mann–Whitney’s test or a non-parametric ANOVA
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(Kruskal–Wallis with Dunn’s multiple comparisons post-test) using GraphPad
Prism 6.0. Results were considered to be significant if p-value < 0.05.
Study approval. The study involving human BC patients was approved by the
Medical Ethical Committee of the Erasmus Medical Center Rotterdam (Nether-
lands) (MEC 02.953). This retrospective study was conducted in accordance with
the Code of Conduct of the Federation of Medical Scientific Societies in the
Netherlands (www.federa.org). Mouse experiments and housing were performed
according to the Dutch guidelines for the care and use of laboratory animals (UL-
DEC-11244).
Data availability
All datasets used to generate the results presented in this study are publicly available.
RNA sequencing data are available in Sequence Read Archive with accession number
SRP127785. Images are publicly available as resource datasets in the Image Data
Resource (IDR) [https://idr.openmicroscopy.org] under accession number idr002269.
Raw data from Figs. 3a, b, 6d, 7a, b, 7d–f and Supplementary Figs. 9B, 10, 11B, 11D–F,
13, 18A, 19B, D, 23A, B, 26, 30B, 30D–H, 31A–F, 32B, C, 33 are provided in a source data
file. All other remaining data are available within the article or supplemental data.
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